课题基金 / 基金详情

项目摘要

项目成果

Erik de Leeuw的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):耐药细菌病原体的流行使目前的抗生素无效,这使得开发新的药物来对抗感染是必要的。防御素是一种抗菌肽,可保护人类免受细菌和病毒感染,作为潜在的抗感染治疗药物具有广泛的应用前景。这项提议首次将细菌膜生物发生中的重要前体Lipid II确定为防御素抗菌活性的潜在靶点。我们研究的总体目标是确定防御素和Lipid II之间的功能和结构相互作用。从长远来看,我们的目标是将研究中获得的知识应用于针对Lipid II的基于防御素的抗生素化合物的开发,以对抗革兰氏阳性病原体感染。 与公共卫生相关:抗生素耐药感染的频率不断上升,共同强调了开发新型抗生素的迫切需要。这个项目首次描述了防御素和类脂II之间的相互作用,防御素是人体内自然产生的抗菌化合物,而类脂II是形成细菌膜的关键因素。我们的研究为防御素如何杀死细菌提供了新的线索,也是将这些天然多肽开发为新型、有效的抗菌剂以对抗感染的重要的第一步。
英文摘要
DESCRIPTION (provided by applicant): The prevalence of resistant bacterial pathogens is rendering current antibiotics ineffective, and making it essential that new drugs be developed to fight infection. Defensins are antimicrobial peptides that protect man against bacterial and viral infections and have a wide range as potential anti-infective therapeutics. This proposal identifies Lipid II, an essential precursor in bacterial membrane biogenesis, as a potential target of defensin antibacterial activity for the first time. The overall objective of our study is to define functional and structural interactions between defensins and Lipid II. In the long term, we aim to apply the knowledge gained in our research towards the development of defensin-based antibiotic compounds targeting Lipid II to combat Gram-positive pathogenic infections. PUBLIC HEALTH RELEVANCE: The escalating frequency of antibiotic resistant infections combined underscores the critical need to develop novel antibiotics. This project describes for the first time the interaction between defensins, naturally occurring antimicrobial compounds in humans and Lipid II, essential in the formation of bacterial membranes. Our research sheds new light on how defensins kill bacteria and is an important first step towards the development of these natural peptides as novel, effective antibiotic agents to combat infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Basis of Human Defensins as Novel Lipid II Binding Peptide Antibiotics
  • 批准号:
    8320100
  • 项目类别:
  • 资助金额:
    $19.19万
  • 财政年份:
    2011
  • 负责人:
    Erik de Leeuw
  • 依托单位:
海外基金